Bristol Myers Squibb (BMY) EBIAT (2016 - 2026)

Bristol Myers Squibb has reported EBIAT over the past 18 years, most recently at $2.7 billion for Q1 2026.

Quarterly EBIAT rose 8.77% to $2.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.0 billion through Mar 2026, up 10.1% year-over-year, with the annual reading at $7.1 billion for FY2025, 178.83% up from the prior year.
EBIAT was $2.7 billion for Q1 2026 at Bristol Myers Squibb, up from $1.1 billion in the prior quarter.
Over five years, EBIAT peaked at $2.7 billion in Q1 2026 and troughed at -$11.9 billion in Q1 2024.
The 5-year median for EBIAT is $1.4 billion (2022), against an average of $485.4 million.
The largest YoY upside for EBIAT was 41900.0% in 2024 against a maximum downside of 238320.0% in 2024.
A 5-year view of EBIAT shows it stood at $2.0 billion in 2022, then fell by 13.63% to $1.8 billion in 2023, then plummeted by 96.54% to $61.0 million in 2024, then surged by 1677.05% to $1.1 billion in 2025, then soared by 147.05% to $2.7 billion in 2026.
Per Business Quant, the three most recent readings for BMY's EBIAT are $2.7 billion (Q1 2026), $1.1 billion (Q4 2025), and $2.2 billion (Q3 2025).

Peer Comparison